series-c-plus
Stage
2020
Founded
3
Investors
About
AdvanCell Isotopes is an Australian company developing 212Pb-based targeted alpha radiotherapeutics and operates a 212Pb isotope manufacturing capability; it is advancing a 212Pb PSMA-targeting radioligand for prostate cancer alongside a pipeline of radiotherapeutic programs.
Explore AdvanCell Isotopes's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.